Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

Journal of the National Cancer Institute
Ian M ThompsonCharles A Coltman

Abstract

Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer. We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy, had at least one PSA measurement and a digital rectal examination (DRE) performed during the year before the biopsy, and had at least two PSA measurements performed during the 3 years before the prostate biopsy. Logistic regression was used to model the risk of prostate cancer and high-grade disease associated with age at biopsy, race, family history of prostate cancer, PSA level, PSA velocity, DRE result, and previous prostate biopsy. Risk equations were created from the estimated logistic regression models. All statistical tests were two-sided. A total of 1211 (21.9%) men were diagnosed with prostate cancer by prostate biopsy. Variables that predicted prostate cancer included higher PSA level, positive family history of prostate cancer, and abnormal DRE resul...Continue Reading

References

Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Apr 24, 2004·American Journal of Epidemiology·Margaret Sullivan PepePolly Newcomb
May 28, 2004·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Oct 21, 2004·Cancer·David G BostwickBarry Timms
Jul 7, 2005·JAMA : the Journal of the American Medical Association·Ian M ThompsonCharles A Coltman

❮ Previous
Next ❯

Citations

Apr 9, 2010·Der Urologe. Ausg. A·P J GoebellB Wullich
Feb 4, 2012·Health Care Management Science·Daniel J UnderwoodBrant A Inman
Jan 12, 2008·Journal of General Internal Medicine·Andrea Gurmankin LevyKatrina Armstrong
Apr 16, 2009·Irish Journal of Medical Science·M R QuinlanD M Quinlan
Nov 10, 2007·Current Oncology Reports·Constance M Johnson, Derek Smolenski
Oct 29, 2010·Current Oncology Reports·Elise D Cook, Ana C Nelson
Aug 16, 2008·Current Urology Reports·Mark Soloway
Feb 24, 2011·Current Urology Reports·David A Levy, J Stephen Jones
Mar 28, 2013·Current Urology Reports·Allison S GlassMatthew R Cooperberg
Aug 3, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Irene Casanova-SalasJose Antonio López-Guerrero
Oct 15, 2013·Asian Journal of Andrology·Shu-Chun KuoChien-Cheng Huang
Apr 9, 2013·Asian Journal of Andrology·Jianfeng XuS Lilly Zheng
Oct 13, 2006·Nature Clinical Practice. Urology·Jan Adolfsson
May 24, 2007·Nature Clinical Practice. Urology·Hans Lilja, Frank O'Brien
Dec 25, 2009·Nature Nanotechnology·Stephen HeartyRichard O'Kennedy
Mar 14, 2008·Nature Reviews. Cancer·Hans LiljaAndrew J Vickers
Jul 7, 2009·Nature Reviews. Urology·David UlmertHans Lilja
Jul 14, 2011·Nature Reviews. Urology·Michael S Borofsky, Danil V Makarov
Dec 19, 2012·Nature Reviews. Urology·Monique J Roobol, Sigrid V Carlsson
Mar 13, 2013·Nature Reviews. Urology·Andrew J Vickers
Jul 22, 2009·Prostate Cancer and Prostatic Diseases·J M FitzpatrickA L Saggerson
May 4, 2011·Prostate Cancer and Prostatic Diseases·M B NicholS J Jacobsen
Jul 6, 2011·Prostate Cancer and Prostatic Diseases·D I ChuL L Bañez
Jul 11, 2012·Prostate Cancer and Prostatic Diseases·K FujitaS Yamaguchi
Jun 5, 2012·Rejuvenation Research·Pierre Olivier LangNikolaos Samaras
Nov 6, 2007·American Journal of Epidemiology·Margaret S PepeYingye Zheng
Jul 10, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HorwichUNKNOWN ESMO Guidelines Working Group
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HorwichUNKNOWN ESMO Guidelines Working Group
Jan 11, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HorwichUNKNOWN European Society for Medical Oncology
Jul 3, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HorwichUNKNOWN ESMO Guidelines Working Group
Dec 1, 2009·Biometrika·Ying Huang, Margaret Sullivan Pepe
Aug 21, 2008·Biostatistics·Wen Gu, Margaret Sullivan Pepe
Feb 18, 2011·International Journal of Epidemiology·Ioanna TzoulakiJohn P A Ioannidis
Apr 20, 2006·Journal of the National Cancer Institute·H Ballentine Carter
Mar 22, 2007·Journal of the National Cancer Institute·Ruth D EtzioniIan M Thompson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.